Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019
December 12 2018 - 8:30AM
Business Wire
Company Placing Priority on Investor
Engagement with New Website, Email Updates
Genprex, Inc. (NASDAQ: GNPX) a
clinical-stage gene therapy company developing a new approach to
treating cancer based upon a novel proprietary technology platform,
announced today that it will be increasing its investor relations
efforts in 2019, spearheaded by the launch of an innovative
corporate website with more robust investor resources, including
the company’s presentations, stock charts and integrated quotes,
SEC filings, news, media coverage, and tailored email newsletters,
among other advanced communication tools. As part of today’s
announcement, investors already have the ability to receive all
news regarding Genprex straight to their inbox by signing up for
the company’s communication list at
https://www.genprex.com/investors/email-alerts/.
In addition to the new investor relations initiatives, Genprex
will also be retaining the services of expert media relations and
public relations firms with the express purpose of increasing the
quantity and improving the quality of investor communications.
Genprex also plans to use modern tools like social media for
greater distribution of news and company announcements. According
to Genprex CEO Rodney Varner, engagement and outreach with
investors will be among the company’s top priorities in 2019.
“We’re extremely excited about the added emphasis on investor
communications and relations in the new year,” said Varner. “We
believe that the drug candidates that we are working to develop
every day at Genprex are groundbreaking and we recognize the
importance in keeping investors abreast of our team’s initiatives
and successes. With the new website and email newsletters we will
be launching, we intend to provide to current and potential
investors unprecedented insight into what is happening at Genprex
as we continue to work at the forefront of the new age of
immunogene therapy cancer treatments.”
The company’s new investor relations initiatives come on the
heels of months of promising developments at Genprex.
In October, Jan Stephens, RN, joined the company’s Cambridge,
Massachusetts office as Genprex’s new Vice President of Clinical
Operations, bringing with her nearly 20 years of comprehensive
clinical operations experience in the biopharma industry and a
specialization in early-to-late stage oncology companies. Stephens
joined the company to help support the various clinical development
programs for Genprex’s proprietary immunogene therapy,
Oncoprex™.
In addition to adding Stephens to its clinical leadership team,
Genprex also entered into a significant agreement with The
University of Texas MD Anderson Cancer Center to extend two option
agreements between Genprex and MD Anderson pertaining to the use of
TUSC2, the active agent in Oncoprex.
Forward-Looking Statements
Statements contained in this press release that are not
statements of historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because these statements are subject to risks and
uncertainties, the actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of TUSC2 on cancer, the services we expect to receive
from media relations and public relations firms and the effect of
those services and statements about Genprex’s business plans. Risks
that contribute to the uncertain nature of the forward-looking
statements include: the presence and level of TUSC2’s effect on
cancer; the ability of media relations and public relations firms
to provide value to the company and the company’s ability to
utilize those services; Genprex’s ability to negotiate and execute
final technology license agreements under the extended options with
MD Anderson; and the nature and scope of protection ultimately
provided under any of the licensed patents and patent applications
should such technology license agreements be executed. These and
other risks and uncertainties are described more fully under the
caption "Risk Factors" and elsewhere in Genprex’s filings and
reports with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Genprex does not
undertake any obligation to update these statements to reflect any
events that occur or facts that exist after the date on which the
statements were made.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing a new approach to treating cancer based upon a novel
proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex™ immunogene therapy for non-small cell
lung cancer (NSCLC). Genprex’s platform technologies are designed
to administer cancer fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then
administered intravenously and taken up by tumor cells where they
express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. Visit the company’s web
site at http://www.genprex.com or follow Genprex on Twitter at
https://twitter.com/genprex and Facebook at
https://www.facebook.com/genprexinc/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181212005202/en/
Investor Contact:GenprexRodney Varnerinvestors@genprex.comPhone:
(512) 537-7997
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024